ArticleSurgical case reports2026
A Case of Long-Term Survival after Multimodal Treatments including Living-Donor Liver Transplantation for a Primary Neuroendocrine Tumor of the Bile Duct.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAn extrahepatic biliary neuroendocrine tumor (EB-NET) is an extremely rare malignancy with a poor prognosis and no established standard of care. CASE PRESENTATION: We herein report the case of a 35-year-old Japanese woman with no significant past medical or family history who presented with epigastric and back pain and was diagnosed with an EB-NET after pylorus-preserving pancreaticoduodenectomy. Despite initial resection, she developed recurrent liver metastases that required repeated hepatic resections and multiple systemic therapies, including chemotherapy, somatostatin analogs, everolimus, and peptide receptor radionuclide therapy (PRRT). Eventually, owing to progressive liver metastasis, she underwent living-donor liver transplantation (LDLT) from her brother 6 years after the initial surgery. Post-transplantation, the patient has remained disease-free for >3 years while on maintenance immunosuppression.
conclusionsMultimodal treatment, including resection of metastases, PRRT, and LDLT, significantly prolonged survival. This case highlights the potential role of LDLT as a curative strategy for patients with EB-NETs and controlled extrahepatic disease following multimodal treatment. Our case suggests that liver transplantation may provide long-term survival even in cases of a rare primary EB-NET, prompting the consideration of broader transplant indications in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.